# SETBP1

Source: https://onco.cc/targets/setbp1/  
OnCo record `setbp1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SETBP1 (SET-binding protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Breast cancer and 5 more.

## Summary

UniProt has no function text for Q9Y6X0; HGNC names it "SET binding protein 1".

CIViC holds 3 clinical evidence items and 0 assertions across 3 variants. Open Targets scores its association with cancer at 0.84 (direct and indirect evidence; datatypes literature 0.95, genetic association 0.83, somatic mutation 0.84, genetic literature 0.83). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Adrenocortical Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: SET binding protein 1; SET-binding protein; KIAA0437
- Tags: cancer-genes-wave
- Symbol: SETBP1
- Class: oncogene
- Biology: UniProt has no function text for Q9Y6X0; HGNC names it "SET binding protein 1". Location: Nucleus (UniProt). Locus 18q12.3 (HGNC).
- Where found: Myeloproliferative neoplasms: Open Targets association 0.77 with myeloproliferative neoplasm (MONDO_0020076); Leukaemia: Open Targets association 0.77 with leukaemia (MONDO_0005059); Breast cancer: Open Targets association 0.66 with breast cancer (MONDO_0007254); Myelodysplastic syndromes / neoplasms: Open Targets association 0.66 with myelodysplastic syndrome (MONDO_0018881); Adrenocortical carcinoma: IntOGen driver in 1 cohort (ACC); Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 3 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Juvenile Myelomonocytic Leukaemia; Atypical Chronic Myeloid Leukaemia, BCR-ABL1 Negative.

## Sources

- HGNC HGNC:15573: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15573
- UniProt Q9Y6X0: https://www.uniprot.org/uniprotkb/Q9Y6X0/entry
- NCBI Gene 26040: https://www.ncbi.nlm.nih.gov/gene/26040
- Ensembl ENSG00000152217: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152217

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Adrenocortical carcinoma](https://onco.cc/cancers/adrenocortical/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/setbp1.json